Financial Performance - The company's operating revenue for Q3 2023 was approximately ¥347 million, representing a year-on-year increase of 58.28%[4] - The net profit attributable to shareholders for Q3 2023 was approximately -¥327 million, with a year-to-date net profit of approximately -¥1.03 billion[4] - Total operating revenue for the first three quarters of 2023 reached RMB 769,470,314.65, a significant increase from RMB 569,635,902.97 in the same period of 2022, representing a growth of approximately 35%[19] - The total operating revenue for Q3 2023 was approximately $769.47 million, an increase from $569.64 million in Q3 2022, representing a growth of 35%[20] - The net profit for Q3 2023 was a loss of approximately $1.03 billion, worsening from a loss of $688.22 million in Q3 2022[20] - The total comprehensive income for Q3 2023 was approximately a loss of $1.04 billion, compared to a loss of $680.11 million in Q3 2022[21] Research and Development - R&D expenses for Q3 2023 totaled approximately ¥318 million, an increase of 49.16% compared to the same period last year[5] - The proportion of R&D expenses to operating revenue was 91.49% for Q3 2023, a decrease of 5.59 percentage points year-on-year[5] - Research and development expenses reached approximately $857.98 million in Q3 2023, compared to $662.54 million in Q3 2022, reflecting a 29.5% increase[20] Assets and Liabilities - The total assets at the end of Q3 2023 were approximately ¥5.51 billion, a decrease of 8.42% from the end of the previous year[5] - As of September 30, 2023, total current assets amounted to RMB 2,235,196,172.88, down from RMB 3,212,137,039.58 at the end of 2022, indicating a decrease of about 30%[16] - The company's total assets decreased to RMB 5,514,357,338.62 from RMB 6,021,189,680.87, reflecting a decline of about 8%[18] - Total liabilities as of September 30, 2023, were RMB 1,558,115,861.03, compared to RMB 1,040,890,051.43 at the end of 2022, indicating an increase of approximately 50%[18] - The company reported a decrease in total equity attributable to shareholders to RMB 3,956,241,477.59 from RMB 4,980,299,629.44, a decline of about 20%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,045[11] - The largest shareholder, HKSCC NOMINEES LIMITED, held 34.83% of the shares, totaling approximately 189.57 million shares[11] Cash Flow - The cash flow from operating activities for the first three quarters of 2023 was negative at approximately $1.11 billion, compared to a negative cash flow of $1.08 billion in the same period of 2022[22] - Cash inflow from investment activities in Q3 2023 totaled approximately $846.96 million, an increase from $685.65 million in Q3 2022[23] - The net cash flow from financing activities in Q3 2023 was approximately $511.63 million, a significant decrease from $2.44 billion in Q3 2022[23] - The ending cash and cash equivalents balance for Q3 2023 was approximately $546.09 million, down from $1.97 billion at the end of Q3 2022[23] Earnings Per Share - The company reported a basic and diluted earnings per share of -¥0.61 for Q3 2023[5] - Basic and diluted earnings per share for Q3 2023 were both -1.91 yuan, compared to -1.32 yuan in Q3 2022[21]
荣昌生物(688331) - 2023 Q3 - 季度财报